# Emapalumab Efficacy in Children With Primary Hemophagocytic Lymphohistiocytosis

> **NCT06587191** · — · ACTIVE_NOT_RECRUITING · sponsor: **Federal Research Institute of Pediatric Hematology, Oncology and Immunology** · enrollment: 7 (estimated)

## Conditions studied

- Primary Hemophagocytic Lymphohistiocytosis

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT06587191
- **Lead sponsor:** Federal Research Institute of Pediatric Hematology, Oncology and Immunology
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-08-01
- **Primary completion:** 2024-09-01
- **Final completion:** 2024-10-01
- **Target enrollment:** 7 (ESTIMATED)
- **Last updated:** 2024-10-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06587191

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06587191, "Emapalumab Efficacy in Children With Primary Hemophagocytic Lymphohistiocytosis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06587191. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*